Cell-based Assays: Technologies and Global Markets

Report Highlights

BCC Research estimates that the global market for cell-based assays will increase at a compound annual growth rate (CAGR) of 12.4% over the next five years to reach $15.2 billion in 2015 and $21.6 billion by 2018 from $12.1 billion in 2013.

Report Includes

• An overview of the global market for cell-based assays available and currently used.
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examinations of major issues involved in the research and development (R&D) of more effective cell-based approaches, for drug discovery, and absorption, distribution, metabolism, and excretion (ADME)/ toxicity assays in development and in use.
• Discussion of current issues and trends affecting the industry, and costs and other factors influencing demand.
• Coverage of new technologies, trends, alliances, and mergers.

Report Scope

This report is an update on Cell-Based Assays: Technologies and Global Markets. It will review global markets for cell-based assays and new developments and will forecast trends for use of these assays for drug discovery and safety and toxicology through 2018. Important assays, technologies and the latest developments, market share by assay type, products on the market and market share by company, and statistical information for types of cancers prevalent worldwide, with a special emphasis on the U.S. market.

The report also includes current issues and trends affecting the industry and costs, and factors influencing demand will be discussed. The report covers products in development, new technologies, trends, alliances and mergers. The report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities.

Analyst Credentials

Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has preclinical, alliance management, discovery and technology development and marketing experience. Her strong focus areas include oncology and cardiovascular diseases, with expertise in molecular and cell biology and complex cell-based biological assays ranging from drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She has experience working with early start-ups.